179 related articles for article (PubMed ID: 35959620)
41. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis.
Burns D; Kula J; Marshall S; Ashworth E; Ornelas M
Adv Ther; 2020 Jul; 37(7):3265-3277. PubMed ID: 32447650
[TBL] [Abstract][Full Text] [Related]
42. The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy.
Warr D
Expert Opin Pharmacother; 2006 Aug; 7(12):1653-8. PubMed ID: 16872268
[TBL] [Abstract][Full Text] [Related]
43. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.
Zhang Y; Yang Y; Zhang Z; Fang W; Kang S; Luo Y; Sheng J; Zhan J; Hong S; Huang Y; Zhou N; Zhao H; Zhang L
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27795228
[TBL] [Abstract][Full Text] [Related]
44. Varicella Zoster Virus Induces Nuclear Translocation of the Neurokinin-1 Receptor, Promoting Lamellipodia Formation and Viral Spread in Spinal Astrocytes.
Bubak AN; Como CN; Blackmon AM; Frietze S; Mescher T; Jones D; Cohrs RJ; Paucek P; Baird NL; Nagel MA
J Infect Dis; 2018 Sep; 218(8):1324-1335. PubMed ID: 29788447
[TBL] [Abstract][Full Text] [Related]
45. NK-1 receptor antagonists: a new generation of anticancer drugs.
Munoz M; Covenas R
Mini Rev Med Chem; 2012 Jun; 12(7):593-9. PubMed ID: 22512565
[TBL] [Abstract][Full Text] [Related]
46. The involvement of the substance P/neurokinin 1 receptor system in viral infection: focus on the gp120 fusion protein and homologous dipeptide domains.
Muñoz M; Coveñas R; Kramer M
Acta Virol; 2019; 63(3):253-260. PubMed ID: 31507190
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic and preventive antiemetic effect of aprepitant in Japanese patients with thoracic malignancies who truly need it.
Ito S; Tsukiyama I; Ando M; Katakami M; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Asai N; Yokoe N; Takahashi A; Baba K; Matsuura K; Yamaguchi E; Kubo A
Support Care Cancer; 2015 Apr; 23(4):905-12. PubMed ID: 25223352
[TBL] [Abstract][Full Text] [Related]
48. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
49. Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: Potential Targets for New Molecular Therapies.
Isorna I; González-Moles MÁ; Muñoz M; Esteban F
J Clin Med; 2023 Oct; 12(19):. PubMed ID: 37835053
[TBL] [Abstract][Full Text] [Related]
50. The In Vitro Pro-inflammatory Functions of the SP/NK1R System in Prostate Cancer: a Focus on Nuclear Factor-Kappa B (NF-κB) and Its Pro-inflammatory Target Genes.
Ebrahimi S; Erfani B; Alalikhan A; Ghorbani H; Farzadnia M; Afshari AR; Mashkani B; Hashemy SI
Appl Biochem Biotechnol; 2023 Dec; 195(12):7796-7807. PubMed ID: 37093533
[TBL] [Abstract][Full Text] [Related]
51. Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy.
Jordan K
Onkologie; 2006 Feb; 29(1-2):39-43. PubMed ID: 16514255
[TBL] [Abstract][Full Text] [Related]
52. Emerging drugs for chemotherapy-induced emesis.
Navari RM; Province PS
Expert Opin Emerg Drugs; 2006 Mar; 11(1):137-51. PubMed ID: 16503832
[TBL] [Abstract][Full Text] [Related]
53. Aprepitant in the prevention of vomiting induced by moderately and highly emetogenic chemotherapy.
Wang SY; Yang ZJ; Zhang Z; Zhang H
Asian Pac J Cancer Prev; 2014; 15(23):10045-51. PubMed ID: 25556423
[TBL] [Abstract][Full Text] [Related]
54. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
55. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
56. Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
Jahn F; Riesner A; Jahn P; Sieker F; Vordermark D; Jordan K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1101-1107. PubMed ID: 26059352
[TBL] [Abstract][Full Text] [Related]
57. Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme.
Afshari AR; Motamed-Sanaye A; Sabri H; Soltani A; Karkon-Shayan S; Radvar S; Javid H; Mollazadeh H; Sathyapalan T; Sahebkar A
Curr Med Chem; 2021; 28(24):4877-4892. PubMed ID: 33441062
[TBL] [Abstract][Full Text] [Related]
58. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting.
Dando TM; Perry CM
Drugs; 2004; 64(7):777-94. PubMed ID: 15025555
[TBL] [Abstract][Full Text] [Related]
59. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2015; 15(10):1127-33. PubMed ID: 26366937
[TBL] [Abstract][Full Text] [Related]
60. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant.
Bergström M; Hargreaves RJ; Burns HD; Goldberg MR; Sciberras D; Reines SA; Petty KJ; Ogren M; Antoni G; Långström B; Eskola O; Scheinin M; Solin O; Majumdar AK; Constanzer ML; Battisti WP; Bradstreet TE; Gargano C; Hietala J
Biol Psychiatry; 2004 May; 55(10):1007-12. PubMed ID: 15121485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
